Back
Biomarin Pharmaceutical Quote, Financials, Valuation and Earnings
Sponsored
BMRN
Sponsored
NOW is the time to get in on this trillion-dollar megatrend
Get it here.
Buy
52
BMRN
Biomarin Pharmaceutical
Last Price:
82.47
Seasonality Move:
6.56%
7 Day Trial
ALL ACCESS PASS
$
7
Master the Market: The Formula for a 96.3% Win Rate Revealed!
Act now!Biomarin Pharmaceutical Price Quote
$82.47
+0.03 (+-1.59%)
(Updated: May 4, 2024 at 6:10 AM ET)
Biomarin Pharmaceutical Key Stats
Buy
52
Biomarin Pharmaceutical (BMRN)
is a Buy
Day range:
$82.32 - $84.80
52-week range:
$76.02 - $99.56
Dividend yield:
0%
P/E ratio:
94.76
P/S ratio:
6.45
P/B ratio:
3.09%
Volume:
1.6M
Avg. volume:
1.7M
1-year change:
-11.9%
Market cap:
$15.7B
Revenue:
$2.4B
EPS:
$1.07
How Much Does Biomarin Pharmaceutical Make?
-
How Much Are Biomarin Pharmaceutical's Sales Annually?
BMRN Revenues are $2.4B -
How Much Profit Does Biomarin Pharmaceutical's Make A Year?
BMRN net income is $167.6M
Is Biomarin Pharmaceutical Growing As A Company?
-
What Is Biomarin Pharmaceutical's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.09% -
What Is Biomarin Pharmaceutical's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0.7%
Biomarin Pharmaceutical Stock Price Performance
-
Did Biomarin Pharmaceutical Stock Go Up Last Month?
Biomarin Pharmaceutical share price went down by -5% last month -
Did BMRN's Share Price Rise Over The Last Year?
BMRN share price fell by -11.9% over the past 1 year
What Is Biomarin Pharmaceutical 52-Week High & Low?
-
What Is Biomarin Pharmaceutical’s 52-Week High Share Price?
Biomarin Pharmaceutical has traded as high as $99.56 over the past 52 weeks -
What Is Biomarin Pharmaceutical’s 52-Week Low Share Price?
Biomarin Pharmaceutical has traded as low as $76.02 over the past 52 weeks
Biomarin Pharmaceutical Price To Free Cash Flow
-
Is Biomarin Pharmaceutical Stock Overvalued?
Biomarin Pharmaceutical is trading at a price to free cash flow ratio of 97.73 -
Is Biomarin Pharmaceutical Stock Undervalued?
Biomarin Pharmaceutical EV to Free Cash Flow ratio is 96.16 -
What Is Biomarin Pharmaceutical’s Price Earnings Growth Ratio?
BMRN PEG ratio is 0.42 -
Is Biomarin Pharmaceutical Trading At A Premium To Earnings?
Biomarin Pharmaceutical EV to EBIT ratio is 61.81
Is It Risky To Buy Biomarin Pharmaceutical?
-
How Much Debt Does Biomarin Pharmaceutical Have?
Total long term debt quarterly is $1.1B -
How Much Cash Does Biomarin Pharmaceutical Have?
Cash and short term investments quarterly total is $1B -
What Is Biomarin Pharmaceutical’s Book Value Per Share?
Book value per share is 26.74
Is Biomarin Pharmaceutical Cash Flow Positive?
-
What Is BMRN Cash Flow From Operations?
Cash flow from operations (TTM) is $280.2M -
What Is Biomarin Pharmaceutical’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$20.8M -
What Is Biomarin Pharmaceutical’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$95.5M
Biomarin Pharmaceutical Return On Invested Capital
-
Is Management Doing A Good Job?
BMRN return on invested capital is 3.45% -
What Is Biomarin Pharmaceutical Return On Assets?
ROA measures how assets are converting to revenues and is 3.07% -
What Is BMRN Return On Equity?
ROE is a measure of profitability and is 4.22%
Biomarin Pharmaceutical Earnings Date & Stock Price
-
What Is Biomarin Pharmaceutical's Stock Price Today?
A single share of BMRN can be purchased today for 82.44 -
What Is Biomarin Pharmaceutical’s Stock Symbol?
Biomarin Pharmaceutical trades on the nasdaq under the ticker symbol: BMRN -
When Is Biomarin Pharmaceutical’s Next Earnings Date?
The next quarterly earnings date for Biomarin Pharmaceutical is scheduled on July 31, 2024 -
When Is BMRN's next ex-dividend date?
Biomarin Pharmaceutical's next ex-dividend date is May 5, 2024 -
How To Buy Biomarin Pharmaceutical Stock?
You can buy Biomarin Pharmaceutical shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Biomarin Pharmaceutical Competitors
-
Who Are Biomarin Pharmaceutical's Competitors?
Below is a list of companies who compete with Biomarin Pharmaceutical or are related in some way:
Biomarin Pharmaceutical Dividend Yield
Data Unavailable
Biomarin Pharmaceutical Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 70.37% | 18.33% |
Revenue: | 8.79% | -0.46% |
Analyst Recommendations
Buy Recommendations: | 14 |
---|---|
Hold Recommendations: | 9 |
Sell Recommendations: | 0 |
Price Target: | 110.02 |
Upside from Last Price: | 33.45% |